Who is sponsoring NCT07271121?

NCT07271121 is sponsored by King Hussein Cancer Center.

What drugs are being tested in NCT07271121?

Interventions in NCT07271121: MB-CART-19.1.

What condition does NCT07271121 study?

NCT07271121 studies Non-Hodgkin Lymphoma Refractory/ Relapsed.

Is NCT07271121 still recruiting?

NCT07271121 is currently recruiting now. Last updated 9 December 2025.

Last reviewed 2025-12-09 · How we verify

NCT07271121

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL

Recruiting now Phase 2 Last updated 9 December 2025

What this trial tests

Phase 2 trial testing MB-CART-19.1 in Non-Hodgkin Lymphoma Refractory/ Relapsed in 26 participants. Currently enrolling.

Timeline

12 February 2025

Primary endpoint
30 March 2028

30 June 2028

Quick facts

Lead sponsor	King Hussein Cancer Center
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	26
Start date	12 February 2025
Primary completion	30 March 2028
Estimated completion	30 June 2028
Sites	1 location across Jordan

Drugs / interventions tested

MB-CART-19.1

Conditions studied

Non-Hodgkin Lymphoma Refractory/ Relapsed — all drugs for Non-Hodgkin Lymphoma Refractory/ Relapsed →

Sponsor

King Hussein Cancer Center — full company profile →

Who can join

Adults 18 to 75, any sex, with Non-Hodgkin Lymphoma Refractory/ Relapsed. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Prospective Single Center, open label, Non-randomized, Single Arm, Single Dose, Phase II Clinical Trial. Adult patients \>18-year-old with CD19+ Non-Hodgkin lymphoma are eligible for the study if they meet eligibility criteria. Patients will receive a fresh single dose of MB-CART-19.1 and will be followed for 12 months and evaluated for efficacy and safety.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Non-Hodgkin Lymphoma Refractory/ Relapsed

Currently open trials in the same condition.

NCT06334991 — Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma · Phase 1 · recruiting

Other King Hussein Cancer Center trials

Trials by the same sponsor.

NCT06689358 — Thoracic Paravertebral Block for Postoperative Pain Management After VATS · NA · completed
NCT04374903 — Hydroxychloroquine in Combination With Sirolimus and Dexamethasone for Treating COVID-19 Patients · NA · withdrawn
NCT04920513 — Universal- Versus Guidelines-Directed Genetic Testing for Germline Pathogenic Variants Utilizing a Multi-Gene Panel for · completed
NCT04920656 — Universal Genetic Testing Versus Guidelines-Directed Testing for Germline Pathogenic Variants Among Non-Western Patients · completed
NCT05057299 — Extramedullary Acute Myeloid Leukemia (eAML): Retrospective Single Center Cohort Study, Clinicopathological, Molecular A · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07271121 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by King Hussein Cancer Center
Last refreshed: 9 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07271121.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing